K Takahashi, PW Serruys, V Fuster, ME Farkouh… - The Lancet, 2020 - thelancet.com
Background Randomised controlled trials are considered the gold standard for testing the efficacy of novel therapeutic interventions, and typically report the average treatment effect …
Background—The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main …
DJFM Thuijs, AP Kappetein, PW Serruys, FW Mohr… - The Lancet, 2019 - thelancet.com
Summary Background The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention …
K Takahashi, PW Serruys, C Gao, M Ono, R Wang… - Circulation, 2021 - Am Heart Assoc
Background: Ten-year all-cause death according to incomplete (IR) versus complete revascularization (CR) has not been fully investigated in patients with 3-vessel disease and …
P Gaba, BJ Gersh, ZA Ali, JW Moses… - Nature Reviews …, 2021 - nature.com
Coronary artery disease is the leading cause of morbidity and mortality worldwide. Selected patients with obstructive coronary artery disease benefit from revascularization with …
G Sarno, S Garg, Y Onuma, JL Gutiérrez-Chico… - The American journal of …, 2010 - Elsevier
The aim of this study was to compare clinical outcome at 5 years in patients with complete and incomplete revascularization treated with coronary artery bypass grafting (CABG) and …
ZA Ali, J Horst, P Gaba, LJ Shaw… - Journal of the …, 2021 - Am Heart Assoc
Guideline‐based medical therapy is the foundation of treatment for individuals with coronary artery disease. However, revascularization with either percutaneous coronary intervention or …